Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
6.33
-0.20 (-3.06%)
At close: Jun 27, 2025, 4:00 PM
6.34
0.00 (0.08%)
After-hours: Jun 27, 2025, 4:00 PM EDT
Kazia Therapeutics Revenue
Kazia Therapeutics had revenue of 22.29K AUD in the half year ending December 31, 2024. This brings the company's revenue in the last twelve months to 2.50M, up 248,983.08% year-over-year. In the fiscal year ending June 30, 2024, Kazia Therapeutics had annual revenue of 2.48M with 248,000.00% growth.
Revenue (ttm)
2.50M AUD
Revenue Growth
+248,983.08%
P/S Ratio
4.10
Revenue / Employee
278,143 AUD
Employees
9
Market Cap
7.08M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 2.48M | 2.48M | 248,000.00% |
Jun 30, 2023 | 1,000.00 | -9.00K | -90.00% |
Jun 30, 2022 | 10.00K | -15.17M | -99.93% |
Jun 30, 2021 | 15.18M | 14.19M | 1,436.54% |
Jun 30, 2020 | 988.11K | -451.89K | -31.38% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KZIA News
- 17 days ago - Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) - PRNewsWire
- 23 days ago - Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer - PRNewsWire
- 6 weeks ago - Kazia Therapeutics Highlights Recent Progress and Provides Business Update - PRNewsWire
- 3 months ago - Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil - PRNewsWire
- 5 months ago - Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer - PRNewsWire
- 5 months ago - Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering - PRNewsWire
- 6 months ago - Kazia Therapeutics Announces $2.0 Million Registered Direct Offering - PRNewsWire
- 6 months ago - Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? - Benzinga